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Abstract A synthetic peptide corresponding to residues 448-
459 of Cl-inhibitor (Cl-inh) binds to Cls, is a non-competitive 
inhibitor of Cls activity and prevents formation of an SDS-stable 
Cls-Cl-inh complex. Substitutions of residues Q452, Q453 or 
F455 in this peptide resulted in loss of Cls binding and inhibitory 
activity of the peptide. NMR analysis of the peptide showed an 
area of well-defined structure from E450 to F455. The side 
chains of Q452, Q453 and Q455 were exposed to the solvent and 
therefore available for Cls binding. The defined structure in the 
peptide is compatible with our computer model of the serpin 
domain of Cl-inh. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Human Cl-inhibitor (Cl-inh) is a single polypeptide chain 
glycoprotein of 478 residues as predicted from cDNA se-
quencing [1,2] with a calculated polypeptide molecular weight 
of 52.8 kDa. On SDS-PAGE it appears as a glycosylated 
protein of apparent MW 115 kDa and 105 kDa under non-
reducing and reducing conditions respectively. Cl-inh belongs 
to the superfamily of serine protease inhibitors (serpins), and 
inactivates proteases of the contact phase (Factor Xlla) [3,4], 
coagulation Factor XIa [3], complement (activated Cl, Clr 
and Cls) [5], tissue-type plasminogen activators [6] and kal-
likrein [5,7]. Cl-inh acts on the Cl molecule both by binding 
to proenzymic Clr and Cls to prevent autoactivation and by 
binding to the activated Clr and Cls proteases in Cl, which 
results in dissociation of Clr and Cls from the Cl complex, in 
the form of a Cl-inh-Clr-Cls-Cl-inh tetramer [8]. During 
interaction of Cl-inh with activated Clr or Cls, the active 
site serine of the protease attacks the peptide bond between 
Arg444 and Thr445 of Cl-inh and an SDS-resistant enzyme-
inhibitor complex is formed [9]. This complex is an enzyme-
substrate or enzyme-product acyl intermediate, which is not 
subsequently hydrolysed. Formation of the complex indicates 
that the product of Cls proteolytic activity, cleaved Cl-inh, is 
likely to have a strong secundary interaction with the pro-
tease, which prevents dissociation of the complex. 
Recent studies on the pathogenesis of acquired Cl-inh de-
ficiency in humans have shown that circulating autoantibodies 
are present in the vast majority of patients [10] and Cl-inh is 
"Corresponding author. Fax: (44) 116-2525030. 
1 Present address: Department of Medicine, School of Medicine, 
Birmingham University, Birmingham B15 2TH, UK. 
usually present in the cleaved (96 kDa) functionally inactive 
form [11]. The Cl-inh deficiency leads to the disease acquired 
or autoimmune angiooedema. In six such patients the anti-Cl-
inh autoantibody recognised an epitope in the distal hinge 
region [12] and converted Cl-inh from an inhibitory pseudo-
substrate to a substrate [13]. The autoantibodies from these 
six patients bound to a synthetic peptide, corresponding to 
residues 448^159, derived from the distal hinge region of 
Cl-inh and the epitope recognised included residues Gin452, 
Gin453, Pro4°4 and Phe455 [12]. This peptide was subsequently 
shown to bind to Cls. Pre-incubation of Cls with the peptide 
prior to the addition of Cl-inh prevented the formation of 
SDS-resistant Cls-Cl-inh complexes and Cl-inh was cleaved 
into a 96 kDa form. These data led us to conclude that the 
distal hinge region of Cl-inh contained a binding site for Cls 
which was (a) distinct from the site of proteolysis by Cls and 
(b) essential for the formation of the SDS-resistant Cls-Cl-
inh complex [14]. 
The present study is concerned with defining the interaction 
of individual residues of Cl-inh with Cls at the secondary 
interaction site. The data presented show that the secondary 
interaction site of Cl-inh is required for regulating Cls activ-
ity and that sequence alterations in the distal hinge region of 
Cl-inh will alter the secondary binding site so that the binding 
of Cls to Cl-inh is diminished. We also provide direct NMR 
evidence to show that the conformation of the residues Gin452 
to Phe455 in the peptide 448^1-59 is similar to that predicted 
for the secondary interaction site in the intact Cl-inh mole-
cule. 
2. Materials and methods 
2.1. Synthetic peptides 
Two peptides, one spanning the proximal hinge region (residues 
428^140, peptide 1, TETGVEAAAASAI) and the other spanning 
the distal hinge region (residues 448^159, peptide 2, VFEVQQPF-
FVL) of Cl-inh and 13 altered peptides derived from peptide 2 
(E450L, E450Q, E450N, Q452E, Q452D, Q453E, Q453D, Q453L, 
Q452L/Q453L, Q452D/Q453D, F455L, F456L and F455L/F457L), 
were obtained from Alta Biosciences (Department of Biochemistry, 
University of Birmingham, UK). 
Activated Cls [15] and Cl-inh [16] were purified by standard tech-
niques. Binding of Cls to solid-phase synthetic peptides was deter-
mined by ELISA [14]. Briefly plates (Falcon, Becton Dickinson Lab-
ware Company, USA) were coated with peptides at 100 ug/ml and 
Cls was used at 10 ug/ml. Bound Cls was detected using anti-human 
Cls (Incstar Ltd., Wokingham, UK) followed by HRP-conjugated 
rabbit antigoat IgG (Incstar). 
Effects of synthetic peptides on Cls enzymic activity were analysed 
using the chromogenic substrate propionyl L-lysyl L-arginine ^-nitro-
anilide hydroacetate (AcOH-C2H5CO-Lys(e-Cbo)-Gly-Arg-pNA) 
(Immuno R Ltd., Heidelberg, Germany) dissolved in 50 mM Tris-
HC1, pH 8.5, containing 25 mM NaCl [14]. 
NMR spectroscopy on peptide 2 was undertaken using a Varian 
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Unity 500 MHz NMR spectrometer at 25°C. The complete assign-
ments of the 2D spectra were based on published methods [17,18]. 
Complete assignments of the 1H-NMR spectra were achieved by fol-
lowing the connectivity along the entire molecule with the combina-
tion of TOCSY and NOESY spectra [19,22]. Full details are given in 
the legend to Fig. 3. 
The secondary Cls binding site on Cl-inh was modelled with Sili-
con Graphics using ovalbumin co-ordinates [23] and confirmed with 
antithrombin III data [24] (provided by Professor Robin Carrell, De-
partment of Haematology, Cambridge University, UK). Residue re-
placements were made according to serpin sequence alignments. 
3. Results and discussion 
Fig. 1A shows progress curves for the inhibition of Cls 
activity by Cl-inh and peptide 2 (both at 25 nM). In the 
presence of Cl-inh, the extent of substrate hydrolysis reached 
a plateau showing that Cl-inh binds tightly to Cls. In con-
trast, peptide 2 slowed the initial rate of substrate hydrolysis, 
but by the end of the incubation period hydrolysis was ap-
proaching completion. Thus peptide 2 is not an irreversible 
inhibitor of Cls activity. Peptide 1 did not affect Cls activity 
(data not shown). The differences in the inhibitory activities of 
Cl-inh and peptide 2 were explored further in second series of 
experiments in which different substrate concentrations 
(1-20 uM), and concentrations of Cl-inh and peptide were 
used with a single fixed concentration of Cls (24 nM). Line-
weaver-Burk plots confirmed that the patterns of inhibition of 
Cls by Cl-inh and peptide 2 were different (Fig. IB), with 
Cl-inh behaving as a competitive inhibitor while peptide 2 
behaved non-competitively. As non-competitive inhibitors 
are able to bind to the enzyme-substrate complex, they must 
bind to a site which is distinct from the enzyme cleft. This 
finding is consistent with our earlier observation that peptide 
2 binds to Cls and, when pre-incubated with Cls, caused 
Cl-inh to behave as a substrate rather than an inhibitor 
[14]. We therefore hypothesised that the distal hinge region 
of Cl-inh contained a secondary binding site for Cls and that 
the interaction of this site with Cls was essential for the for-
mation of SDS-stable Cls-Cl-inh complexes [14]. Peptide 2 
would therefore act by binding to Cls, and preventing Cl-inh 
from binding to the same site. 
In order to determine which residues in peptide 2 contribute 
to the secondary binding site for Cls a series of peptide 2 
Fig. 1. A: Kinetic assays for the inhibition of Cls activity by 
Cl-inh and peptide 2. Cls and Cl-inh were dialysed against 10 mM 
Tris-HCl, pH 8.0, containing 100 mM NaCl and 1 mM EDTA. The 
chromogen was dissolved in 50 mM Tris-HCl, pH 8.0, containing 
25 mM NaCl to provide a stock solution with a concentration of 
36 uM. All final reaction volumes were adjusted to 800 ul using 
10 mM Tris-HCl, pH 8.0, containing 100 mM NaCl. Progress 
curves were performed with concentrations of Cls, Cl-inh and pep-
tide each at 25 nM and chromogen at a concentration of 15 |iM. 
Immediately after Cls, Cl-inh or peptides and chromogen were 
mixed, the absorbance changes were recorded at 450 nM for 50 
cycles at 60 s intervals using a Perkin Elmer spectrophotometer. 
B,C: The concentration of Cls was kept at 24 nM in each reaction. 
Cl-inh was added to final concentrations of 10, 24 or 30 nM while 
peptide 2 was added to final concentrations of 24, 30 or 48 nM. 
The mixing of Cls and inhibitor was followed immediately by the 
addition of a series of different concentrations of chromogen (final 
concentration 1-20 |iM in 20 reaction mixtures) for each concentra-
tion of Cl-inh or peptide. The absorbance changes were then re-
corded automatically at 405 nm. The initial reaction velocity (V0) 
for each reaction was calculated from data recorded for 20 cycles at 
20 s intervals. B: Cl-inh; C: peptide 2. 
derivatives was investigated for Cls binding and Cls inhibi-
tory activities. The substitutions Q452E, Q452D, Q453E, 
Q453D, Q453L and F455L showed marked reduction in Cls 
binding (Fig. 2, top) and inhibition of Cls activity (Fig. 2, 
bottom). Substitutions of L or Q for E at position 450 did not 
affect Cls binding or activity, indicating that this residue does 
not contribute significantly to the secondary binding site for 
Cls. These data indicate that the residues Q452, Q453 and 
F455 of Cl-inh are involved in the binding of Cls at the 
secondary binding site and, in peptide 2, are involved in the 
regulation of Cls activity. 
The structural basis for the interaction of peptide 2 with 
Cls was investigated by NMR spectrometry. Complete assign-
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Fig. 2. Top: Effect of sequence variation in peptide 2 on binding to Cls and inhibition of Cls enzymic activity. Peptides were dissolved in 
20 mM Tris-HCl, pH 7.6, 150 mM NaCl and 10% (v/v) DMSO and then diluted in coating buffer (15 mM Na 2C0 3 , 3.5 mM NaHC0 3 , 
pH 9.6) to final peptide concentrations of 100 |xg/ml. ELISA plates were coated by incubating 100 JJ.1 of solution/well overnight at 4°C. Non-
specific binding sites were blocked by incubation with 0.1% gelatin in PBS. Cls (10 u.g/ml in PBS) was added and incubated at 37°C for 1 h fol-
lowed by addition of goat anti-human Cls (1:2000 dilution in PBS) at room temperature for a further 2 h and then anti-goat immunoglobulin, 
conjugated with horseradish peroxidase (HRP; 1:4000). Incubation was carried out at room temperature for a further 2 h. The plate was 
washed 3 times in PBS, containing 0.2% (v/v) Tween 20, between each step. The plate was developed using OPD (2.1% (w/v) o-phenylenedi-
amine dihydrochloride in 22 mM sodium citrate, 56 mM Na2HPO<4, pH 5.0, and 5% (v/v) of fresh 30% H2O2). The reaction was stopped by 
addition of 4 M H2SO4 and the absorbance was read at 490 nm. Bottom: Kinetic assay for the effect of peptide 2 and its derivatives on Cls 
activity. A standard inhibition curve was constructed using a fixed concentration of Cls and synthetic peptide (both at 24 nM). This series of 
reactions was pre-incubated at 37°C for 30 min before the addition of the chromogen to a final concentration of 10 |xM. The absorbance 
changes at 405 nm were then recorded at 20 s intervals for 6 min. The percentage of residual Cls activity was calculated using the equation 
( 1 - ^ ) X 1 0 0 
x 
where x = slope for Cls alone andy = slope of Cls in presence of peptide. 
merits of the ' H - N M R spectra were achieved by following the combination of TOCSY and N O E S Y spectra. Molecular 
connectivity along the entire length of peptide 2 with the modelling revealed a well-defined structure from E450 to 
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Fig. 3. NMR solution structures of peptide 2. The NMR sample of the peptide was dissolved in water of 50 mM sodium phosphate containing 
10% (v/v) DMSO, with pH 7.6 to a final concentration of 14 mM. All NMR spectra were recorded on a Varian Unity 500 MHz NMR spec-
trometer at 25C. The complete resonance assignments of the NMR spectra were achieved by following the connectivity along the entire peptide 
with the combination of TOCSY and NOESY spectra [17-22]. Molecular modelling was carried out by using the simulated dynamics [24-27] 
of the Biosym DISCOVER program with the distance constraints from NOESY spectra [28-30]. A: Superimposition of eight conformations of 
the peptide. B: Plots of the structure with side chains of Gln452-Gln453-Pro454-Phe455 displayed in the rigid region of the peptide. C: More de-
tailed structure of the conformation of the region comprising Gln452-Gln453-Pro454-Phe45B residues. 
F455 (Fig. 3), with the ends of the peptide exhibiting flexible 
folding tendencies. The side chains of Q452, Q453 and F455 
are all exposed to the solvent, in agreement with our computer 
model of the intact serpin domain of Cl-inh (Fig. 4). 
The replacement of either Q452 or Q453 by glutamate 
greatly reduced Cls binding, indicating that both residues 
serve as hydrogen bond donors rather than acceptors. Thus 
it is possible that the binding of these residues to Cls is asso-
ciated with a cluster of negatively changed residues in Cls. 
The interaction of these Cls residues with the secondary bind-
ing site on Cl-inh would help to maintain a tight hydrophobic 
contact between enzyme and inhibitor in the primary interac-
tion site. Although the mechanism by which the SDS-resistant 
serpin-enzyme complex is formed is not yet fully understood, 
the maintenance of such a hydrophobic contact between an 
enzyme and a serpin is probably essential for the inhibitory 
function of the serpins, as it excludes small molecules (e.g. 
water molecules) from the acyl group formed between inhib-
itor and enzyme. 
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Fig. 4. Computer modelling of Cl-inh molecule. A Cl-inh model was created with Silicon Graphics using ovalbumin [23] coordinates. When 
differences in amino acid sequence occurred, the ovalbumin residue was replaced by the Cl-inh residue [12]. The results were confirmed using 
antithrombin III data [24]. A: Serpin domain model of Cl-inh based on ovalbumin crystal structure. The reactive site residue (Arg444) is la-
belled. The proximal hinge is to the right of the reactive site residue and the distal hinge is to the left. One of the residues of secondary Cls 
binding site (Gin452) is labelled. B: Close-up view of reactive site loop of Cl-inh showing side chains of amino acid residues, with Arg444 la-
belled. C: Close-up view of the secondary Cls binding site showing aromatic ring Phe291 and the indole ring of His292. The nitrogen-containing 
residues of Gin452 and Gin453 are shown. The aromatic ring of Phe455 is located to the right of Gin453 (unlabelled). 
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